Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi

Affiliation auteurs!!!! Error affiliation !!!!
TitrePhase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi
Type de publicationJournal Article
Year of Publication2018
AuteursLesniewski-Kmak K., Moiseenko V., Saunders M., Wasan H., Argiles G., Borg C., Creemers G., Fedyanin M., Glynne-Jones R., Pfeiffer P., Punt C., Stroyakovskiy D., A. Tije T, van de Wouw A., Kanehisa A., Fougeray R., N. Busto L, Amellal N., Van Cutsem E.
JournalANNALS OF ONCOLOGY
Volume29
Pagination108
Date PublishedJUN
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1093/annonc/mdy149.021